⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923738 | 0.72 | — | — | |
| SCHEMBL23143475 | 0.71 | CYP11B2 (0.44) | — | |
| SCHEMBL2991270 | 0.70 | CHRNB2 (0.39) | — | |
| SCHEMBL9923741 | 0.70 | — | — | |
| SCHEMBL2989851 | 0.69 | — | — | |
| SCHEMBL2981867 | 0.68 | MAPK1 (0.31) | — | |
| SCHEMBL2991527 | 0.68 | GABRG2 (0.35) | — | |
| SCHEMBL13382 | 0.64 | PLK4 (0.34) | — | |
| SCHEMBL23143476 | 0.64 | DRD4 (0.47) | — | |
| SCHEMBL24282441 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216966-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-12-22 | — | — | US | disclosed |
| US-9034871-B2 | Compounds for Alzheimer's disease | Manfredi, John (US) | 2015-05-19 | — | — | US | disclosed |
| EP-1809601-B1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20130261118-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MANFREDI JOHN (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120225873-A1 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225845-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYREXIS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100184975-A1 | COMPOUNDS FOR ALZHEIMBER'S DISEASE | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678823-B2 | N-phenylindoles; oral dosage forms; side effect reduction | Myriad Pharmaceticals, Inc. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090099179-A1 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-16 | — | — | US | disclosed |
| EP-2010187-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249135-A1 | N-phenylindoles; oral dosage forms; side effect reduction | MYRIAD GENETICS, INCORPORATED (US) | 2008-10-09 | — | — | US | disclosed |
| WO-2007115306-A2 | COMPOUNDS FOR DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| EP-1809601-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006041874-A2 | COMPOUNDS FOR ALZHEIMER'S DISEASE | MYRIAD GENETICS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |